Sarcoidosis: Difference between revisions

From IDWiki
(Imported from text file)
 
 
(One intermediate revision by the same user not shown)
Line 1: Line 1:
−
== Pathophysiology ==
+
==Pathophysiology==
   
−
* Thought to be related to abnormal T-cell activation
+
*Thought to be related to abnormal T-cell activation
   
−
== Differential Diagnosis ==
+
==Differential Diagnosis==
   
−
* Hilar lymphadenopathy
+
*Hilar lymphadenopathy
−
** Sarcoidosis
+
**Sarcoidosis
−
** Infection: TB, fungal, HIV, mycoplasma
+
**Infection: TB, fungal, HIV, mycoplasma
−
** Malignancy: lymphoma
+
**Malignancy: lymphoma
−
** Others
+
**Others
   
−
== Scadding Classification ==
+
==Scadding Classification==
   
−
# Stage I: Bilateral hilar lymphadenopathy (70% resolve)
+
#Stage I: Bilateral hilar lymphadenopathy (70% resolve)
−
# Stage II: Above, with interstitial lung disease (50% resolve)
+
#Stage II: Above, with interstitial lung disease (50% resolve)
−
# Stage III: Interstitial lung disease alone (15% resolve)
+
#Stage III: Interstitial lung disease alone (15% resolve)
−
# Stage IV: Fibrotic, "burnt out" lungs (0% resolve)
+
#Stage IV: Fibrotic, "burnt out" lungs (0% resolve)
   
−
== Risk Factors ==
+
==Risk Factors==
   
−
* Women more than men (2:1)
+
*Women more than men (2:1)
−
* More common in African-Americans
+
*More common in African-Americans
   
−
== Clinical Presentation ==
+
==Clinical Manifestations==
   
−
=== Extrapulmonary disease ===
+
===Extrapulmonary disease===
   
−
* Skin: Erythema nodosum and lupus pernio, and others
+
*Skin: Erythema nodosum and lupus pernio, and others
−
* Cardiac: 40% of patients, though only 5-10% are symptomatic
+
*Cardiac: 40% of patients, though only 5-10% are symptomatic
−
* CNS: 5-10%, multiple presentations
+
*CNS: 5-10%, multiple presentations
−
* Eyes: 10% of all uveitis cases, usually bilateral
+
*Eyes: 10% of all uveitis cases, usually bilateral
−
* Hypercalcemia
+
*Hypercalcemia
−
* Nephrocalcinosis
+
*Nephrocalcinosis
   
−
== Diagnosis ==
+
==Diagnosis==
   
−
* Evidence of granulomatous inflammation (often on BAL or EBUS) without infection
+
*Evidence of granulomatous inflammation (often on BAL or EBUS) without infection
−
* Either lung involvement or multiorgan involvement
+
*Either lung involvement or multiorgan involvement
   
−
== Investigations ==
+
==Investigations==
   
−
* Labs
+
*Labs
−
** CBC, lytes, creatinine, calcium, liver panel
+
**CBC, lytes, creatinine, calcium, liver panel
−
* Imaging
+
*Imaging
−
** High-res CT scan
+
**High-res CT scan
−
* Other
+
*Other
−
** PFTs: most commonly restrictive with decreased DLCO, but can show combined restriction-obstruction, or rarely any other pattern. Often normal.
+
**PFTs: most commonly restrictive with decreased DLCO, but can show combined restriction-obstruction, or rarely any other pattern. Often normal.
−
** EKG for cardiac involvement
+
**EKG for cardiac involvement
−
** Eye exam for uveitis
+
**Eye exam for uveitis
   
−
== Management ==
+
==Management==
   
−
* Only treat if symptomatic, as many will resolve spontaneously
+
*Only treat if symptomatic, as many will resolve spontaneously
−
** Spontaneous remission depends on Scadding stage (I 70%, II 50%, III 15%, IV 0%)
+
**Spontaneous remission depends on Scadding stage (I 70%, II 50%, III 15%, IV 0%)
−
* Prednisone 20-40mg daily for 8-12 weeks, then taper
+
*Prednisone 20-40mg daily for 8-12 weeks, then taper
−
** Add vitamin D and calcium if serum calcium is low
+
**Add vitamin D and calcium if serum calcium is low
−
** Can still use bisphosphates for bone protection
+
**Can still use bisphosphates for bone protection
−
* Second-line steroid-sparing agents include
+
*Second-line steroid-sparing agents include
−
** Methotrexate
+
**Methotrexate
−
** Azathioprine, leflonamide, MMF, hydroxychloroquine, thalidomide
+
**Azathioprine, leflonamide, MMF, hydroxychloroquine, thalidomide
−
** TNG-alpha inhibitors are last line
+
**TNG-alpha inhibitors are last line
   
−
=== Management by organ system ===
+
===Management by organ system===
   
  +
{| class="wikitable"
−
{|
 
−
! Organ
+
!Organ
−
! Clinical Features
+
!Clinical Features
−
! Treatment
+
!Treatment
 
|-
 
|-
−
| Lungs
+
|Lungs
−
| Dyspnea w FEV1 or FVC <70%
+
|Dyspnea w FEV1 or FVC <70%
−
| Prednisone 24-40 mg/day
+
|Prednisone 24-40 mg/day
 
|-
 
|-
−
| Lungs
+
|Lungs
−
| Cough, wheeze
+
|Cough, wheeze
−
| Inhaled corticosteroid
+
|Inhaled corticosteroid
 
|-
 
|-
−
| Eyes
+
|Eyes
−
| Anterior uveitis
+
|Anterior uveitis
−
| Topical corticosteroid
+
|Topical corticosteroid
 
|-
 
|-
−
| Eyes
+
|Eyes
−
| Posterior uveitis
+
|Posterior uveitis
−
| Prednisone 20-40 mg/day
+
|Prednisone 20-40 mg/day
 
|-
 
|-
−
| Eyes
+
|Eyes
−
| Optic neuritis
+
|Optic neuritis
−
| Prednisone 20-40 mg/day
+
|Prednisone 20-40 mg/day
 
|-
 
|-
−
| Skin
+
|Skin
−
| Lupus pernio
+
|Lupus pernio
−
| Prednisone 20-40 mg/day<br />Hydroxychloroquine 400 mg/day<br />Thalidomide 100-150 mg/day<br />Methotrexate 10-15 mg/week
+
|Prednisone 20-40 mg/day<br />Hydroxychloroquine 400 mg/day<br />Thalidomide 100-150 mg/day<br />Methotrexate 10-15 mg/week
 
|-
 
|-
−
| Skin
+
|Skin
−
| Plaques or nodules
+
|Plaques or nodules
−
| Prednisone 20-40 mg/day<br />Hydroxychloroquine 400 mg/day
+
|Prednisone 20-40 mg/day<br />Hydroxychloroquine 400 mg/day
 
|-
 
|-
−
| Skin
+
|Skin
−
| Erythema nodosum
+
|Erythema nodosum
−
| NSAID
+
|NSAID
 
|-
 
|-
−
| CNS
+
|CNS
−
| Cranial nerve palsies
+
|Cranial nerve palsies
−
| Prednisone 20-40 mg/day
+
|Prednisone 20-40 mg/day
 
|-
 
|-
−
| CNS
+
|CNS
−
| Intracerebral involvement
+
|Intracerebral involvement
−
| Prednisone 40 mg/day<br />Azathioprine 150 mg/day<br />Hydroxychloroquine 400 mg/day
+
|Prednisone 40 mg/day<br />Azathioprine 150 mg/day<br />Hydroxychloroquine 400 mg/day
 
|-
 
|-
−
| Heart
+
|Heart
−
| Complete heart block
+
|Complete heart block
−
| Pacemaker
+
|Pacemaker
 
|-
 
|-
−
| Heart
+
|Heart
−
| Ventricular fibrillation or tachycardia
+
|Ventricular fibrillation or tachycardia
−
| AICD
+
|AICD
 
|-
 
|-
−
| Heart
+
|Heart
−
| Decreased LVEF &lt;35%
+
|Decreased LVEF &lt;35%
−
| AICD and prednisone 30-40 mg/day
+
|AICD and prednisone 30-40 mg/day
 
|-
 
|-
−
| Liver
+
|Liver
−
| Cholestatic hepatitis with constitutional symptoms
+
|Cholestatic hepatitis with constitutional symptoms
−
| Prednisone 20-40 mg/day<br />Ursodiol 15 mg/kg per day
+
|Prednisone 20-40 mg/day<br />Ursodiol 15 mg/kg per day
 
|-
 
|-
−
| MSK
+
|MSK
−
| Arthralgias
+
|Arthralgias
−
| NSAID
+
|NSAID
 
|-
 
|-
−
| MSK
+
|MSK
−
| Granulomatous arthritis
+
|Granulomatous arthritis
−
| Prednisone 20-40 mg/day
+
|Prednisone 20-40 mg/day
 
|-
 
|-
−
| MSK
+
|MSK
−
| Myositis or myopathy
+
|Myositis or myopathy
−
| Prednisone 20-40 mg/day
+
|Prednisone 20-40 mg/day
 
|-
 
|-
−
| Calcium
+
|Calcium
−
| Kidney stones, fatigue
+
|Kidney stones, fatigue
−
| Prednisone 20-40 mg/day<br />Hydroxychloroquine 400 mg/day
+
|Prednisone 20-40 mg/day<br />Hydroxychloroquine 400 mg/day
 
|}
 
|}
   
 
from the [NEJM sarcoidosis review article][1]
 
from the [NEJM sarcoidosis review article][1]
   
−
== Further Reading ==
+
==Further Reading==
   
−
* [1]: Iannuzzi MC, Rubicki BA, and Teirstein AS. [https://doi.org/10.1056/NEJMra071714 Sarcoidosis]. ''N Engl J Med''. 2007 Nov 22;357(21):2153-65.
+
*[1]: Iannuzzi MC, Rubicki BA, and Teirstein AS. [https://doi.org/10.1056/NEJMra071714 Sarcoidosis]. ''N Engl J Med''. 2007 Nov 22;357(21):2153-65.
−
* Costabel U and Hunninghake GW. [https://erj.ersjournals.com/content/14/4/735.long ATS/ERS/WASOG statement on sarcoidosis]. ''Eur Respir J''. 1999 Oct;14(4):735-7.
+
*Costabel U and Hunninghake GW. [https://erj.ersjournals.com/content/14/4/735.long ATS/ERS/WASOG statement on sarcoidosis]. ''Eur Respir J''. 1999 Oct;14(4):735-7.
   
 
[[Category:Rheumatology]]
 
[[Category:Rheumatology]]

Latest revision as of 15:56, 7 September 2020

Pathophysiology

  • Thought to be related to abnormal T-cell activation

Differential Diagnosis

  • Hilar lymphadenopathy
    • Sarcoidosis
    • Infection: TB, fungal, HIV, mycoplasma
    • Malignancy: lymphoma
    • Others

Scadding Classification

  1. Stage I: Bilateral hilar lymphadenopathy (70% resolve)
  2. Stage II: Above, with interstitial lung disease (50% resolve)
  3. Stage III: Interstitial lung disease alone (15% resolve)
  4. Stage IV: Fibrotic, "burnt out" lungs (0% resolve)

Risk Factors

  • Women more than men (2:1)
  • More common in African-Americans

Clinical Manifestations

Extrapulmonary disease

  • Skin: Erythema nodosum and lupus pernio, and others
  • Cardiac: 40% of patients, though only 5-10% are symptomatic
  • CNS: 5-10%, multiple presentations
  • Eyes: 10% of all uveitis cases, usually bilateral
  • Hypercalcemia
  • Nephrocalcinosis

Diagnosis

  • Evidence of granulomatous inflammation (often on BAL or EBUS) without infection
  • Either lung involvement or multiorgan involvement

Investigations

  • Labs
    • CBC, lytes, creatinine, calcium, liver panel
  • Imaging
    • High-res CT scan
  • Other
    • PFTs: most commonly restrictive with decreased DLCO, but can show combined restriction-obstruction, or rarely any other pattern. Often normal.
    • EKG for cardiac involvement
    • Eye exam for uveitis

Management

  • Only treat if symptomatic, as many will resolve spontaneously
    • Spontaneous remission depends on Scadding stage (I 70%, II 50%, III 15%, IV 0%)
  • Prednisone 20-40mg daily for 8-12 weeks, then taper
    • Add vitamin D and calcium if serum calcium is low
    • Can still use bisphosphates for bone protection
  • Second-line steroid-sparing agents include
    • Methotrexate
    • Azathioprine, leflonamide, MMF, hydroxychloroquine, thalidomide
    • TNG-alpha inhibitors are last line

Management by organ system

Organ Clinical Features Treatment
Lungs Dyspnea w FEV1 or FVC <70% Prednisone 24-40 mg/day
Lungs Cough, wheeze Inhaled corticosteroid
Eyes Anterior uveitis Topical corticosteroid
Eyes Posterior uveitis Prednisone 20-40 mg/day
Eyes Optic neuritis Prednisone 20-40 mg/day
Skin Lupus pernio Prednisone 20-40 mg/day
Hydroxychloroquine 400 mg/day
Thalidomide 100-150 mg/day
Methotrexate 10-15 mg/week
Skin Plaques or nodules Prednisone 20-40 mg/day
Hydroxychloroquine 400 mg/day
Skin Erythema nodosum NSAID
CNS Cranial nerve palsies Prednisone 20-40 mg/day
CNS Intracerebral involvement Prednisone 40 mg/day
Azathioprine 150 mg/day
Hydroxychloroquine 400 mg/day
Heart Complete heart block Pacemaker
Heart Ventricular fibrillation or tachycardia AICD
Heart Decreased LVEF <35% AICD and prednisone 30-40 mg/day
Liver Cholestatic hepatitis with constitutional symptoms Prednisone 20-40 mg/day
Ursodiol 15 mg/kg per day
MSK Arthralgias NSAID
MSK Granulomatous arthritis Prednisone 20-40 mg/day
MSK Myositis or myopathy Prednisone 20-40 mg/day
Calcium Kidney stones, fatigue Prednisone 20-40 mg/day
Hydroxychloroquine 400 mg/day

from the [NEJM sarcoidosis review article][1]

Further Reading